Efficacy and Safety Study of Ingavirin® to Treat Influenza and Acute Respiratory Viral Infections in Patients 13-17 y.o.
- Conditions
- Acute Respiratory InfectionCommon ColdInfluenza, HumanViral Infection
- Interventions
- Drug: Placebo oral capsule
- First Posted Date
- 2017-07-02
- Last Posted Date
- 2017-07-02
- Lead Sponsor
- Valenta Pharm JSC
- Target Recruit Count
- 161
- Registration Number
- NCT03206346
- Locations
- 🇷🇺
GBOU VPO "Kazan State Medical University" of Ministry of Health of Russian Federation, Kazan', Russian Federation
🇷🇺City Pediatric Outpatient Clinic number 5, Perm, Russian Federation
🇷🇺Research Institute of Influenza, Ministry of Healthcare of Russian Federation, Saint Petersburg, Russian Federation
Efficacy and Safety Study of Ingavirin® to Treat Influenza and Acute Respiratory Viral Infections in Children 7-12 y.o.
- Conditions
- Acute Respiratory InfectionViral InfectionCommon ColdInfluenza, Human
- Interventions
- Drug: Placebo oral capsule
- First Posted Date
- 2017-06-19
- Last Posted Date
- 2017-06-19
- Lead Sponsor
- Valenta Pharm JSC
- Target Recruit Count
- 310
- Registration Number
- NCT03191097
- Locations
- 🇷🇺
GBOU VPO "Kazan State Medical University" of Ministry of Health of Russian Federation, Kazan', Russian Federation
🇷🇺Rostov State Medical University, Rostov-na-Donu, Russian Federation
🇷🇺I.M. Sechenov First Moscow State Medical University, Moscow, Russian Federation
Study of Post-Exposure Ingavirin® Prophylaxis of Influenza and Acute Respiratory Viral Infections
- Conditions
- Influenza, HumanFluAcute Respiratory InfectionViral InfectionCommon Cold
- Interventions
- Drug: Placebo oral capsule
- First Posted Date
- 2017-06-16
- Last Posted Date
- 2017-06-16
- Lead Sponsor
- Valenta Pharm JSC
- Target Recruit Count
- 400
- Registration Number
- NCT03189537
- Locations
- 🇷🇺
Saratov State Medical University named after V. I. Razumovsky, Saratov, Russian Federation
🇷🇺Research Institute of Influenza, Saint Petersburg, Russian Federation
Efficacy and Safety Study of Ingavirin® 90 mg Once Daily to Treat Influenza and Other Acute Viral Infections in Adults
- Conditions
- Common ColdInfluenza, HumanAcute Respiratory Infection
- Interventions
- Drug: Placebo
- First Posted Date
- 2017-05-16
- Last Posted Date
- 2017-05-16
- Lead Sponsor
- Valenta Pharm JSC
- Target Recruit Count
- 445
- Registration Number
- NCT03154515
- Locations
- 🇷🇺
N.F. Gamaleya Scientific Research Institute of Epidemiology and Microbiology, Moscow, Russian Federation
🇷🇺State budgetary health care institution novosibirsk region "city clinical infectious diseases hospital no. 1", Novosibirsk, Russian Federation
🇷🇺State educational institution of higher professional education "Chelyabinsk State Medical Academy of Federal Agency of Health Care and Social Development", Chelyabinsk, Russian Federation
Efficacy and Safety Study of Ingavirin® to Treat Influenza and Other Acute Respiratory Viral Infections in Patients 3-6 y.o.
- Conditions
- Common ColdInfluenza
- Interventions
- Drug: placebo
- First Posted Date
- 2015-12-31
- Last Posted Date
- 2016-06-09
- Lead Sponsor
- Valenta Pharm JSC
- Target Recruit Count
- 190
- Registration Number
- NCT02644018
- Locations
- 🇷🇺
FGBU "Scientific center of children health" of the Ministry of Health of Russian Federation, Moscow, Russian Federation
🇷🇺Children's city outpatients clinic № 5, Perm, Russian Federation
🇷🇺I.M. Sechenov First Moscow State Medical University, Moscow, Russian Federation